Can the DIO2 rs225014 C allele contribute to tissue-level hypothyroid symptoms despite normal TSH?

The DIO2 rs225014 C (Thr92Ala) polymorphism plays a critical role in tissue-specific thyroid hormone regulation, acting as a functional hypomorphic variant that decouples local thyroid signaling from systemic hormone levels.

Mechanistic explanations

• Accelerated enzyme degradation: The Thr-to-Ala substitution occurs within an 18-residue instability loop of the type 2 deiodinase (D2) enzyme, promoting increased ubiquitination and rapid proteasomal degradation.
• Reduced local T3 generation: This accelerated turnover decreases the active enzyme pool, reducing effective intracellular T4-to-T3 conversion capacity by 20% to 40% in target tissues.

Clinical implications and symptoms

• Tissue-level hypothyroidism: Because D2 generates the majority of intracellular T3 required for local nuclear receptor binding, its impairment causes localized cellular hypothyroidism in D2-dependent tissues, such as the brain and skeletal muscle.
• Decoupling from systemic TSH: Systemic markers like thyroid-stimulating hormone (TSH) and free T4 often remain within normal reference ranges due to central hypothalamic-pituitary-thyroid axis compensation, masking tissue-specific deficits.
• Persistent hypothyroid symptoms: This local signaling mismatch explains why some carriers experience persistent cognitive impairment, fatigue, and depression despite having "normal" TSH levels, and why some patients show clinical improvement or express a preference for L-T4/L-T3 combination therapy over L-T4 monotherapy.

Bottom line

• The DIO2 rs225014 C allele reduces intracellular deiodination capacity through accelerated enzyme degradation, causing tissue-specific hypothyroidism and persistent symptoms (such as fatigue and cognitive issues) even when circulating TSH remains completely normal.